Yervoy(ipilimumab)
Yervoy (ipilimumab) is an antibody pharmaceutical. Ipilimumab was first approved as Yervoy on 2011-03-25. It is used to treat melanoma in the USA. It has been approved in Europe to treat colorectal neoplasms, malignant mesothelioma, melanoma, non-small-cell lung carcinoma, and renal cell carcinoma. The pharmaceutical is active against cytotoxic T-lymphocyte protein 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Yervoy
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ipilimumab
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Yervoy | ipilimumab | Bristol Myers Squibb | N-125377 RX | 2011-03-25 | 2 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| yervoy | Biologic Licensing Application | 2023-02-15 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ipilimumab, Yervoy, Bristol-Myers Squibb Company | |||
| 2027-10-02 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J9228 | Injection, ipilimumab, 1 mg |
Clinical
Clinical Trials
903 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lung neoplasms | D008175 | HP_0100526 | C34.90 | 12 | 24 | 8 | 1 | 3 | 41 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 17 | 4 | 1 | 6 | 30 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 2 | 4 | — | 1 | 2 | 8 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 33 | 56 | 14 | — | 21 | 114 |
| Neoplasms | D009369 | — | C80 | 24 | 34 | 1 | — | 1 | 45 |
| Carcinoma | D002277 | — | C80.0 | 9 | 27 | 5 | — | 6 | 43 |
| Non-small-cell lung carcinoma | D002289 | — | — | 11 | 23 | 7 | — | 5 | 38 |
| Prostatic neoplasms | D011471 | — | C61 | 5 | 20 | 3 | — | — | 24 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 4 | 10 | 2 | — | — | 15 |
| Small cell lung carcinoma | D055752 | — | — | 4 | 10 | 2 | — | — | 13 |
| Colorectal neoplasms | D015179 | — | — | 5 | 9 | 1 | — | — | 12 |
| Adenocarcinoma | D000230 | — | — | 4 | 8 | 1 | — | 1 | 12 |
| Squamous cell carcinoma | D002294 | — | — | 2 | 6 | 1 | — | — | 8 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 6 | 9 | — | — | — | 12 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 9 | — | — | 1 | 11 |
| Urologic neoplasms | D014571 | — | C64-C68 | 5 | 5 | — | — | — | 7 |
| Transitional cell carcinoma | D002295 | — | — | 5 | 5 | — | — | — | 7 |
| Sarcoma | D012509 | — | — | 3 | 6 | — | — | — | 6 |
| Multiple myeloma | D009101 | — | C90.0 | 3 | 4 | — | — | — | 5 |
| Uveal neoplasms | D014604 | EFO_1001230 | — | 1 | 4 | — | — | — | 5 |
| Cutaneous malignant melanoma | D000096142 | — | — | 3 | 1 | — | — | 1 | 5 |
| Lymphoma | D008223 | — | C85.9 | 3 | 3 | — | — | — | 4 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 2 | 2 | — | — | — | 4 |
Show 60 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
| Astrocytoma | D001254 | EFO_0000271 | — | 1 | — | — | — | — | 1 |
| Neurofibrosarcoma | D018319 | — | — | 1 | — | — | — | — | 1 |
| Nerve sheath neoplasms | D018317 | EFO_0000760 | — | 1 | — | — | — | — | 1 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | — | — | — | — | 1 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | 1 | — | — | — | — | 1 |
| Hiv-2 | D015498 | — | — | 1 | — | — | — | — | 1 |
| Immunologic deficiency syndromes | D007153 | HP_0002721 | D84.9 | 1 | — | — | — | — | 1 |
Show 8 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autoimmune diseases | D001327 | HP_0002960 | M30-M36 | — | — | — | — | 1 | 1 |
| Hepatitis c | D006526 | — | B19.2 | — | — | — | — | 1 | 1 |
| Hepatitis b | D006509 | — | — | — | — | — | — | 1 | 1 |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | — | 1 | 1 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ipilimumab |
| INN | ipilimumab |
| Description | Ipilimumab (human mab) |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >7SU0:H,I|Fab heavy chain
(PCA)VQLVESGGGVVQPGRSLRLSCAASGFTFSHYTMHWVRQAPGKGLEWVTFISYDGHNKYYADSVKGRFTISRDNSK
NTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT
VSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCGGHHHHHH
>7SU0:L,M|Fab light chain
EIVLTQSPGTLSLSPGERATLSCRASQEVGESELAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLE
PEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 5TRU, 5XJ3, 6JC2, 6RP8, 7SU0, 7SU1 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1789844 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06186 |
| UNII ID | 6T8C155666 (ChemIDplus, GSRS) |
Target
Agency Approved
CTLA4
CTLA4
Organism
Homo sapiens
Gene name
CTLA4
Gene synonyms
CD152
NCBI Gene ID
Protein name
cytotoxic T-lymphocyte protein 4
Protein synonyms
CD152, celiac disease 3, CTLA-4, cytotoxic T lymphocyte associated antigen 4 short spliced form, Cytotoxic T-lymphocyte-associated antigen 4, cytotoxic T-lymphocyte-associated serine esterase-4, gluten-sensitive enteropathy, insulin-dependent diabetes mellitus 12, ligand and transmembrane spliced cytotoxic T lymphocyte associated antigen 4
Uniprot ID
Mouse ortholog
Ctla4 (12477)
cytotoxic T-lymphocyte protein 4 (P09793)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Yervoy – Bristol Myers Squibb
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 46,351 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
39,586 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use